original ) (raw )Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Lesley Robson , Nicola Curtin
Clinical Cancer Research, 2008
View PDFchevron_right
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity
Giuseppe Nocentini
View PDFchevron_right
Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Miguel Fuertes
Recent Patents on Anti-Cancer Drug Discovery, 2006
View PDFchevron_right
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity
Bernardo Ruggeri
Molecular Cancer Therapeutics, 2007
View PDFchevron_right
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Larry Rubinstein
Journal of Clinical Oncology, 2009
View PDFchevron_right
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Nicola Curtin
Molecular Cancer Therapeutics, 2007
View PDFchevron_right
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site
Ilaria Portarena
2002
View PDFchevron_right
Pharmacological Modulation of Poly(ADP-ribose) Polymerase-Mediated Cell Death: Exploitation in Cancer Chemotherapy
Miguel Fuertes
Molecular Pharmacology, 2003
View PDFchevron_right
Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines
Barbara Durkacz , Nicola Curtin
Clinical Cancer Research an Official Journal of the American Association For Cancer Research, 2000
View PDFchevron_right
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
N Curtin
Cancer Chemotherapy and Pharmacology, 2013
View PDFchevron_right
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies
Nicola Curtin
Clinical cancer research : an official journal of the American Association for Cancer Research, 2003
View PDFchevron_right
Poly (ADP) Ribose Polymerase Inhibition: A Potential Treatment of Malignant Peripheral Nerve Sheath Tumor
Ian McCutcheon
Cancer Biology & Therapy, 2015
View PDFchevron_right
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor
Andres J P Klein-Szanto
Molecular cancer therapeutics, 2003
View PDFchevron_right
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region
Gabriella Fabbrocini
2005
View PDFchevron_right
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality
Alessandra Cesano
Molecular medicine (Cambridge, Mass.), 2011
View PDFchevron_right
Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
Larry Rubinstein
Clinical Cancer Research, 2008
View PDFchevron_right
Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors
Barbara Durkacz , Nicola Curtin
British journal of cancer, 1995
View PDFchevron_right
Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis
Silvie Timmers
Biochemical and Biophysical Research Communications, 2006
View PDFchevron_right
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells
Ilaria Portarena
Glia, 2002
View PDFchevron_right
Activation of Poly(adenosine diphosphate–ribose) Polymerase in Mouse Tumors Treated by Photodynamic Therapy¶
Mladen Korbelik
Photochemistry and Photobiology, 2003
View PDFchevron_right
Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: An Early Marker of Chemotherapy-induced Apoptosis1
Guy Poirier
2000
View PDFchevron_right
The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer
Katarzyna Zubik
Nowotwory. Journal of Oncology, 2022
View PDFchevron_right
Modeling Pharmacodynamic Response to the Poly(ADP- Ribose) Polymerase Inhibitor ABT-888 in Human
Jiuping Ji
2016
View PDFchevron_right
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
Shahneen Sandhu
European Journal of Cancer, 2010
View PDFchevron_right
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
luis rodriguez
Clinical Cancer Research, 2007
View PDFchevron_right
Effects of PTEN Status on Poly (ADP-ribose) Polymerase Inhibition in Addition to Radiation and Temozolomide in Glioblastoma
Kamalakannan Palanichamy
International Journal of Radiation Oncology Biology Physics, 2011
View PDFchevron_right